FDA Updates

Inviro Medical Devices has introduced an integral write-on stripe, Invirostripe, to its complete line of manually retractable InviroSNAP! safety syringes.

Novartis has received final approval for its combination product, Exforge, used to treat hypertension.

Ambrisentan (Letairis) in 5-and 10-mg tablets has been approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).

Rxs, OTCs, Home Health Care, Health and Beauty, and miscellaneous items

Long-acting levocetirizine (Xyzal, UCB/Sanofi-Aventis) has received regulatory approval for the relief of symptoms associated with seasonal and perennial allergic rhinitis and for uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children six years of age and older.

New products for prescription drugs, OTC, home health, health and beauty

New immunosuppressive regimens that combine Certican and low-dose Neoral to preverse renal function following heart transplants and Viagra to lower pulmonary arterial heypertension are coming soon to hospitals.

New products comprising prescription drugs, OTCs, healthcare items, beauty care.

New branded drugs, generics, OTCs, home health, health and beauty care items

From coughs and colds to analgesics, pharmacists give their top two OTC brand recommendations in this exclusive Drug Topics survey.

Rxs, generics, OTCs, home healthcare items

Drug Topics' exclusive OTC Recommendation Survey 2007 finds that R.Ph.s are providing more OTC recommendations and counseling than ever.

Traditional facial moisturizers and skin lotions are passé to many observers of this field.

Which over-the-counter and health and beauty care brands accounted for the most dollar sales in drugstores, supermarkets, and mass-mercahndisers last year?

New pharmacy products, new indications for existing products.

Patients suffering from irritable bowel syndrome with constipation or chronic constipation will no longer have the option of treatment with tegaserod (Zelnorm).

New Rx New Generics

What follows is a review of the biggest news of 2006 in just a few categories, along with their new product standouts.

The FDA recommends that you counsel patients on the importance of reading product labels carefully to determine the active ingredients and dosing instructions of each product and to discourage them from making assumptions about use based on product names or appearance. The use of similar trade names (so-called "brand-name families") is common practice for OTC products. The products with the trade names "Sudafed" and "Sudafed PE" illustrate specific concerns.

A group of researchers at the University of Florida College of Pharmacy recently submitted a citizen's petition asking the Food & Drug Administration to increase the maximum allowable dose of phenylephrine (PE) from 10 mg to 25 mg and to withdraw approval of phenylephrine for children under 12 years of age. The petition also called for additional research to validate the safety and effectiveness of the higher recommended dose.

The new guide recommends that physicians start with nonpharmacologic treatments such as exercise, physical therapy, weight loss, and heat or cold therapy. If there is no relief of pain, physicians should consider acetaminophen, aspirin, and even short-term use of narcotic analgesics as a first step, taking the patient's medical history into account.

New product Newswire

Mission Pharmacal, San Antonio, (210) 696-8400, is introducing a new prenatal vitamin. Citracal Prenatal 90 + DHA was formulated for women before, during, and after pregnancy. The product contains life'sDHA-a vegetarian form of DHA omega-3-along with prescription-strength vitamins and minerals.

Mission Pharmacal, San Antonio, (210) 696-8400, is introducing a new prenatal vitamin. Citracal Prenatal 90 + DHA was formulated for women before, during, and after pregnancy. The product contains life'sDHA-a vegetarian form of DHA omega-3-along with prescription-strength vitamins and minerals.

Pharmacists appear pleased with the Food & Drug Administration's recent decision to allow orlistat 60-mg capsules to go over the counter (OTC) in the United States. (See Latebreakers, Feb. 19.) The OTC version, to be marketed by GlaxoSmithKline beginning this summer under the brand name alli, is for use by overweight adults 18 years and older in conjunction with a reduced-calorie, low-fat diet.

A new specialty certification may be on the horizon. The Board of Pharmaceutical Specialties (BPS) could offer ambulatory care certification as early as 2008. "BPS got the ball rolling, but we have not committed to the development of this specialty," said BPS executive director Richard Bertin. "It is up to the profession to present arguments, pro and con, before that decision can be made."

Migraines are now viewed as a chronic disorder with episodic manifestations, and emphasis should be put on evaluating impairment between headache attacks. This is the gist of a new consensus statement recently released by the National Headache Foundation (NHF), an organization focusing on migraine prevention.